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ABSTRACT
The scope and trajectory of today’s escalating 
antimicrobial resistance (AMR) crisis is inadequately 
captured by existing surveillance systems, particularly 
those of lower income settings. AMR surveillance systems 
typically collate data from routine culture and susceptibility 
testing performed in diagnostic bacteriology laboratories to 
support healthcare. Limited access to high quality culture 
and susceptibility testing results in the dearth of AMR 
surveillance data, typical of many parts of the world where 
the infectious disease burden and antimicrobial need 
are high. Culture and susceptibility testing by traditional 
techniques is also slow, which limits its value in infection 
management. Here, we outline hurdles to effective 
resistance surveillance in many low- income settings and 
encourage an open attitude towards new and evolving 
technologies that, if adopted, could close resistance 
surveillance gaps. Emerging advancements in point- of- 
care testing, laboratory detection of resistance through or 
without culture, and in data handling, have the potential to 
generate resistance data from previously unrepresented 
locales while simultaneously supporting healthcare. 
Among them are microfluidic, nucleic acid amplification 
technology and next- generation sequencing approaches. 
Other low tech or as yet unidentified innovations could 
also rapidly accelerate AMR surveillance. Parallel advances 
in data handling further promise to significantly improve 
AMR surveillance, and new frameworks that can capture, 
collate and use alternate data formats may need to be 
developed. We outline the promise and limitations of such 
technologies, their potential to leapfrog surveillance over 
currently available, conventional technologies in use today 
and early steps that health systems could take towards 
preparing to adopt them.
INTRODUCTION
Leapfrog technologies, innovations that 
overcome seemingly intractable barriers to 
progress, can have extraordinary impact in 
low- and middle- income countries (LMIC). 
For example, the African mobile phone 
explosion removed the need for networks of 
telephone cabling and led to huge advances 
in data sharing and the availability of banking. 
Similarly, localised solar and wind technolo-
gies are emerging as practical alternatives for 
electrification of distant locations.
There is a global consensus that antimi-
crobial resistance (AMR) is a critical global 
health problem. The systematic identifica-
tion of bacterial pathogens and their asso-
ciated AMR patterns allows clinicians to use 
antimicrobials judiciously in individuals and 
to design locally relevant antimicrobial stew-
ardship guidelines, reducing selective pres-
sure on the emergence of multidrug- resistant 
strains of the major species infecting humans 
and livestock. This information is also essen-
tial for estimating the burden that AMR adds 
to poor patient outcomes and healthcare 
Summary box
 ► Surveillance is essential for qualifying and quanti-
fying antimicrobial resistance but is inadequately 
conducted in many low- income and middle- income 
settings due to technical hurdles.
 ► Our review of the current implementation and de-
velopment landscape reveals that leapfrog technol-
ogies that could overcome some of these hurdles are 
in existence or could soon become available.
 ► Low- and middle- income countries settings with 
few surveillance facilities should be encouraged and 
supported to embrace out- of- the- Petri dish innova-
tions rather than model their surveillance systems 
solely on difficult- to- implement- and- quality- assure 
traditional methods.
 ► Lower income health systems can and should posi-
tion themselves to adopt promising leapfrog tech-
nologies by upgrading financial and procurement 
systems, moving to digital health records and in-
tegrating molecular biology into medical laboratory 
science education.
2 Okeke IN, et al. BMJ Global Health 2020;5:e003622. doi:10.1136/bmjgh-2020-003622
BMJ Global Health
costs. AMR surveillance is therefore a critical, often 
neglected, component of AMR control that is needed, 
but least available, in LMIC settings. What innovations, 
now and in the future, could leapfrog these problems?
HURDLES TO ANTIMICROBIAL RESISTANCE SURVEILLANCE IN 
RESOURCE-LIMITED SETTINGS
The gold standard approach to bacterial resistance 
surveillance remains culturing organisms from clinical 
specimens in quality assured microbiology laboratories, 
testing their susceptibility against a limited panel of anti-
microbial drugs, and disseminating the resulting data 
to surveillance networks and healthcare professionals. 
Even where available, this slow process may not provide 
information fast enough to influence immediate care 
or guide antimicrobial stewardship. Despite the chal-
lenges of culture- based methods, they remain the main 
tool supporting patient care and informing empirical 
antimicrobial selection and surveillance and much- 
needed surveillance data is therefore lacking.1–3 There 
are model LMIC settings where surveillance is strong 
but establishing quality assured laboratory networks has 
proven too complex or costly to be implemented in many 
resource- limited parts of the world, particularly within 
Africa.4 Where this approach has been successful, it has 
often been in the context of extramurally- supported 
academic or industrial ventures. There is currently new 
commitment, support and activity towards building 
new culture- based LMIC surveillance systems. However, 
scale- up is slow,5 6 sustainability remains in question and 
an outside- the- Petri- dish review of surveillance possibili-
ties is overdue.
In many resource- limited settings, formidable hurdles 
hamper implementation of AMR surveillance based on 
traditional culture and susceptibility testing. These fall 
into three broad categories (table 1): (1) pre- laboratory, 
which prevent taking a sample and adequate metadata 
and delivering these to a quality assured testing in a 
usable condition, (2) laboratory, which prevent optimal 
specimen processing, and (3) data dissemination, which 
reduce the utility of susceptibility information that is 
generated. As indicated in table 1, there are advances 
to eliminate or at least lower many of these hurdles in 
existence or in development but a truly leapfrog tech-
nology would eliminate multiple steps in the traditional 
pathway to surveillance (figure 1), eliminate a roadblock 
for which no solution exists (eg, invasive sampling) or 
create an entirely new pathway to surveillance.
CLOSING THE DISTANCE BETWEEN PATIENTS AND TESTING
Patients and their healthcare providers are often distant 
from labs that typically test using expensive equipment, 
labile consumables and highly trained staff, all of which 
are in short supply.7 In high- income countries (HICs), 
fewer resource constraints allow better decentralisation of 
laboratory services. Remote access to specialised testing is 
a global problem solved in HICs by tiered systems linked 
by specimen transport couriers to centralised facilities. 
Courier services are inadequately networked, dependent 
on poorly developed road infrastructure and/or unreli-
able in many LMIC settings and therefore not optimal 
for routine or urgent sample transport. Specimen collec-
tion riders that can meet (and where necessary sample) 
individuals at remote locations represent a significant 
and tailored advance but still require some road infra-
structure and significant expense for the most remote 
settings.8 Drones, already a successful alternative to road- 
based transportation in medical supply chains (Rwanda) 
or blood products (Malawi), could potentially repre-
sent a truly leapfrog alternative that can reach the most 
remote settings if cost and patient sampling barriers can 
be overcome.3
Point- of- care tests could make sample transport unnec-
essary if they could identify bacterial infections in a manner 
that is affordable, sensitive, specific, user- friendly, rapid 
and robust, equipment- free and deliverable: ‘ASSURED’.9 
In reality, tests that meet these criteria and identify resis-
tant infections remain to be deployed. A target product 
profile (TPP) for such a point- of- care test would specify 
that it should be equipment- free, require no electricity 
to ship, store or perform, and produce reliable results in 
under 30 min. It would discriminate multiple pathogens 
associated with a specific syndrome and would be able to 
read out, or be paired with a second rapid test that iden-
tifies, AMR. TPPs along these lines have been issued for 
gonococcal clinical diagnostics and surveillance10 and 
similar profiles would be applicable for febrile illnesses, 
meningitis and invasive diarrhoea. A decade ago, it would 
have been challenging or impossible to respond to such a 
TPP. Today, technological innovations with the power to 
promote point- of- care testing at the hardest- to- reach loca-
tions along these lines exist, as has been reviewed exten-
sively elsewhere.11–13 The products themselves remain to 
be finalised in part because they represent relatively new 
innovations still in development, but also because their 
markets, in a world where gold- standard AMR data are 
considered to be an output of quality assured diagnostic 
microbiology laboratories, is presently uncertain.
To effectively link bedside caregiving to surveillance 
systems, testing innovations need to be paired with data 
handling innovations.14 Ideally, health facilities would 
record patient, clinical microbiology and treatment data 
in real time, and warning systems would alert healthcare 
workers to collect clinical specimens for bacteriology 
investigations before antibiotic prescription orders are 
filled. Further data would only be entered once. As smart-
phones with camera and video functions are increasingly 
available, technologies to assist clinical practice and deci-
sions should be but a simple app away. However, data 
handling is a foremost surveillance challenge and one 
that might be easier to address with point- of- care testing 
that provides results immediately to clinicians. However, 
it may be challenging to link aetiologic information from 
point- of- care testing to AMR surveillance because current 
bacterial resistance surveillance systems are isolate- based.
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Table 1 Common antimicrobial surveillance hurdles in low- resource and remote settings
The hurdle Structure of the hurdle Potential solutions
Access to testing  ► Difficulties in transporting patients and/or their 
specimens to laboratories
 ► Lack of a supply chain for diagnostic resources 
needed for conventional testing
 ► Absence of phlebotomy
 ► Pathogen is too fastidious to culture in a 
minimally equipped bacteriology lab (eg, 
Mycobacterium, Neisseria, Campylobacter and 
Helicobacter)
 ► Existing surveillance systems not set up to 
accept point- of- care results that may be relevant 
to resistance
 ► Alternative or autonomous transportation systems
 ► Point of care/near patient technologies that is, 
GeneXpert, BioFire, loop- mediated isothermal 
amplification- based technologies, nanopore- 
based sequencing and point- of- care single 
nucleotide polymorphisms detection systems in 
development
Invasive sampling and 
associated biohazards
 ► Absence of skilled healthcare workers that can 
retrieve specimens from normally sterile sites 
(Blood and CSF culture)
 ► High body fluid volumes required for some tests 
(eg, blood culture)
 ► Poor access to adequate biosafety resources and 
safe waste disposal
 ► Automated devices that can safely and aseptically 
retrieve blood, and possibly other specimens
 ► Tests that allow interrogation of smaller or non- 
invasive samples
 ► Point- of- care technologies
Data- entry and handling Paper records that cannot be queried or viewed from 
more than one location
 ► Next generation LIMS systems with secure 
access via mobile devices




 ► High overhead costs for properly assured 
laboratory practice or low quality testing due to 
skipping essential quality assurance
Integrated quality assurance such as read quality 
analyses for WGS
In- lab processing time Long incubation time makes direct benefits for 
testing patients requiring urgent care, or who cannot 
return to the laboratory for test results doubtful
 ► Rapid nucleic acid- based testing
 ► Systems that accelerate pathogen growth or 
allow for its early detection
 ► Provision of intelligent data visualisation to guide 
empiric Rx/decision support/risk management
Subtyping  ► Subtyping is the most specialised part of testing 
needed for surveillance and therefore the least 
likely to be performed accurately. It is also 
typically the most expensive
 ► Many subtyping techniques are difficult or 
irreproducible and may not give the same results 
each time even when properly performed
 ► Subtyping methods differ from one species to 
another, so laboratories can often not house 
expertise and resources for typing a broad range 
of organisms
 ► Subtyping is essential for delineating some 
pathogens and for identifying outbreaks
Rapid WGS with microfluidic DNA preparation, which 
can provide fine subtyping information along with 
identification and susceptibility information at no 
extra cost. To reduce costs, other methods are often 
batched at the species level, leading to longer turn- 
around times. WGS is as effective without species 
batching
Quality assurance Access to external quality assurance is difficult in 
many resource settings
 ► Some aspects of WGS can be remotely assured
 ► Fully automated point- of- care devices
The cold- chain Current testing requires a large number of different 
reagents requiring cold storage to be shipped to 
testing laboratories
 ► Stable reagents that can be transported at 
ambient temperatures and humidity
 ► Unified testing methods such as WGS that 
allow the same reagents to be used for different 
organism types
 ► Lab- on- chip technology that circumvents these 
issues
Human resources There is a shortage of qualified laboratory 
technicians and a wide range of skills is needed for 
broad surveillance
 ► Tests that have broad range so that the same 
suite of skills can be applied to different 
pathogens
 ► Automated or kit- based testing requiring lower 
skill levels
 ► Tele- training and other training formats that 
permit on- the- job training for existing technicians
Continued
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LEAPFROGGING WITHIN LABORATORIES, OR THE HARE AND 
THE TORTOISE REVISITED
AMR surveillance information is typically generated 
from sequential culture- based methods of bacterial isola-
tion, identification and susceptibility testing (figure 1). 
Most bacterial culture media are comprised of cheap 
components and other requirements are simple; modest 
upgrades from the time of Robert Koch.3 Superficially, 
this might appear to be an appropriate technology 
when resources are constrained given its cost, apparent 
simplicity and long history, but in practice this is not 
the case.7 Outcomes from LMIC Quality Assurance 
programmes indicate that, when performed, identifi-
cation and susceptibility testing is associated with high 
error rates outside of highly controlled environments 
such as provided by quality assured microbiology labo-
ratories.7 15 16 To date, establishing quality- assured labo-
ratory networks has proven complex and costly for many 
resource- limited parts of the world, including many sites 
in Africa.4 5 This, in turn, limits diagnostic stewardship 
in which clinicians and healthcare workers understand 
recommended guidelines, perform appropriate diag-
nostic tests (particularly bacterial culture if indicated), 
and use local AMR surveillance data to provide the most 
optimal treatment.17
1. Shortening turn-around times
The first step in traditional bacteriology is pathogen 
recovery. Paradoxically, waiting for ‘fast- growing’ patho-
gens to multiply is the major reason why routine bacterial 
culture is so slow. For some pathogen- specimen combi-
nations, ‘Gold- Standard’ culture methods only recover 
the pathogen in a fraction of instances, so leapfrog 
solutions with greater sensitivity will have global value. 
Cases in point include cerebrospinal fluid processing 
in meningitis, particularly in pretreated patients, and 
low- abundance blood- borne bacteria like Salmonella 
enterica serovariety Typhi, a key AMR priority pathogen. 
To address these limitations, which are not large in well- 
resourced settings, technology has largely used ‘tortoise’ 
advancements to culture- based protocols which margin-
ally extend the sensitivity, specificity and speed attain-
able for identifying a huge diversity of bacteria and 
AMR phenotypes. Even the most innovative ‘tortoise’ 
advancements speed up or eliminate one or more incu-
bation steps but typically still require some growth.18–20 
More sensitive or alternate growth- detection technolo-
gies can drastically reduce turn- around times and repre-
sent longer stride tortoise strategies, often with unfortu-
nately hefty price tags. Automated culture, identification 
and sensitivity testing systems such as BACTEC, BacT/
Alert or VersaTREK (blood culture) and VITEK and 
VITEK- MS, Phoenix, Bruker MALDI Biotyper or Sensi-
titre (identification and/or susceptibility testing), as 
well as DNA- leakage or early growth- detection tests18–20 
accomplish this and, in some cases, are easier to quality 
assure than traditional protocols. Even shorter incuba-
tion times could be possible from ultrasensitive detection 
platforms in development.21 22 Because they still require 
basic specimen and isolate management and are expen-
sive to institute and run, these generally do not constitute 
leapfrog technologies for LMICs although some have 
been deployed.
The hurdle Structure of the hurdle Potential solutions
Infrastructure Electricity, running water and internet access are 
often unavailable or only intermittently available at 
remote testing sites
 ► Equipment that can run off- line for example, 
portable sequencers, foldoscopes and 
paperfuges
 ► Leapfrog energy and water solutions
Data sharing and 
connectivity
Personal data needs to be protected and be 
compliant with General Data Protection Regulation 
and pseudonymised before sharing. Robust 
protocols are not always in place
 ► Standards followed.
 ► Data gathering systems from all diagnostics.
 ► Context appropriate connectivity via local telecom 
systems
 ► Easy- to- use data visualisation
CSF, cerebrospinal fluid; LIMS, laboratory information management systems; WGS, whole- genome sequencing.
Table 1 Continued
Figure 1 Existing options for leapfrogging across the path 
from patient (1) to surveillance data (6) that traditionally 
includes manual health- worker collection of specimen and 
patient data (2), isolate recovery (3), identification (4) and 
antimicrobial susceptibility testing (AST) (5), with incubation 
during steps 2 to 5, followed by data entry and processing 
(6). NAAT, nucleic acid amplification technology.
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Challenging or dangerous- to- culture pathogens have 
provided intrinsic motivation for bypassing culture and 
provide leapfrog models. Analogous technologies for 
detecting antibacterial resistance largely do not exist but 
these new methods could serve as important templates. 
A recently described Lab- on- a- Chip, built from comple-
mentary metal- oxide- semiconductor technology coupled 
with loop- mediated isothermal amplification addresses 
common Plasmodium resistance single nucleotide poly-
morphisms (SNPs) in malaria23 and could feasibly do the 
same for bacterial resistance conferred by SNPs. While 
culture- free technologies offer significant promise, many 
alternatives to culture narrow the range of organisms that 
can be identified and most have the added disadvantage 
of not capturing the infecting organism for archiving and 
future research.
Antimicrobial panels for susceptibility testing are 
selected based on the identity of infectious pathogens 
and naming and subtyping are the most complicated and 
least generalisable protocols by traditional testing. It is 
sometimes possible to base identification on bacterial 
cell membrane composition, or its impact on the host 
immune system. These options open the possibility of 
antigen- based or antibody- based diagnostics, which, in 
turn, present the possibility of field- ready platforms such 
as microfluidic systems, simpler mobile- readable lateral- 
flow devices or at least protocols to remove one or more 
of the sequential steps needed for routine identification 
by culture.24 25 In a few instances, a surface- expressed 
resistance- conferring protein can serve as a marker for 
AMR but those represent the exception.26 All of these 
approaches could be difficult to multiplex and until 
that challenge is addressed, their use for multiaetiologic 
syndromes where bacteria predominate as pathogens will 
be limited.
2. Promises and pitfalls of nucleic acid amplification tests
One oft- cited leapfrog technology for AMR surveil-
lance that offers the opportunity to bundle pathogen 
identification, subtyping, and in many cases resistance 
profiling too, is nucleic acid amplification technology 
(NAAT), for example by PCR, in which oligonucleotide 
primers bind to a complementary DNA target, permit-
ting specific amplification and thence detection of one 
or more signature fragments. All nucleic acid- based tests, 
including NAAT and whole- genome sequencing (WGS; 
discussed in the next section), have the disadvantage of 
identifying resistance genotypes rather than phenotypes. 
As some genes, including many encoding resistance, 
are not expressed and new resistance genes can only 
be identified after they are known, nucleic acid- based 
AMR surveillance cannot completely replace phenotypic 
methods, which must continue to be performed at some 
level in each health system.
In spite of this caveat, NAAT is widely used in research, 
has long since superseded culture in diagnostic virology 
laboratories but as with culture, PCR is an easy thing 
to do badly. NAATs often depend on samples being 
appropriately taken from patients and delivered in a 
timely fashion to a quality assured facility, although 
NAAT is certainly faster than culture. The limitations of 
NAAT are exquisitely illustrated by the challenges seen in 
both LMIC and HIC settings during the first few months 
of the COVID-19 pandemic when real- timePCR was the 
only diagnostic option for the disease and could only be 
performed in very few diagnostic laboratories. However, 
the subsequent scale- up in testing in virtually every 
country in the world demonstrates the potential of these 
technologies for select applications.
When performed from first principles, NAAT tests are 
exceptionally prone to contamination, which is then diffi-
cult to detect, but some of this shortfall can be addressed 
by test format innovation, and microfluidics advances 
have made it possible to automate temperamental prepa-
ratory steps.27 Lab- on- chip, discs and cards can effectively 
bypass inadequate human resources, infrastructure and 
sometimes cold- chains.28 The GeneXpert MTB/RIF plat-
form is an example of one such leapfrog technology and 
the BioFire FilmArray represents another. The former has 
been more widely deployed in LMIC settings and consists 
of automated PCR system initially and most commonly 
used for tuberculosis diagnostics and rifampicin sensi-
tivity testing. As with BioFire, it requires less training than 
conventional PCR as all the specimen processing steps are 
completed within the cartridge and has therefore circum-
vented many of these problems. GeneXpert MTB/RIF 
has been widely deployed in a range of LMIC settings and 
appears to be cost- effective in at least some of them.29–31 
However, even this system shares the challenge presented 
by low copy number bacteria, which may certainly be 
the case in paucibacillary mycobacterial disease. Poten-
tial solutions to insensitivity include new technologies 
and applications of nucleic acid- based methods such as 
single- cell whole genome sequence Clustered Regularly 
Interspaced Short Palindromic Repeats (CRISPR)- based 
detection32 as well as free DNA capture as applied in fetal 
abnormality and cancer screening tests.33
For relatively difficult- to- culture bacteria, including 
mycobacteria, and sexually- transmitted bacteria, NAAT- 
based tests have overcome diagnostic and surveillance 
roadblocks in LMIC laboratories. Xpert and BioFire tests 
that detect priority resistant pathogens that are easier to 
culture, such as methicillin- resistant Staphylococcus aureus 
and carbapenemase- producing Enterobacteriaceae 
are commercially available and approved for use at the 
point of care.34–37 However, these are not marketed or 
prioritised in low- income settings even when the Xpert 
hardware already exists in admittedly overstretched 
tuberculosis programmes, where it has been applied 
to other diagnostics, most notably for Ebola and now 
COVID-19.38 Even in the best resourced settings, NAAT 
cannot compete with culture in terms of the diversity of 
bacteria and AMR types it can identify as there is a limit 
to the degree to which assays are multiplexed. In AMR 
surveillance, NAAT is comparable to the hare that raced 
ahead of culture, but which has yet to cross the line into 
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routine surveillance on a large scale and may well be 
overtaken by other technologies.11
3. Whole-genome sequencing-based surveillance in LMICs
Beyond those bacterial pathogens that are challenging 
to culture, today’s exemplar leapfrog technology 
remains WGS, which has been revolutionised by the 
introduction of inexpensive, rapid and high throughput 
next- generation sequencing technology. Such equip-
ment still requires significant laboratory infrastructure 
and advanced equipment maintenance and information 
technology support.39 40 Nonetheless, second- generation 
sequencing technologies have been used in local 
outbreak situations, such as the Ebola, Zika, COVID-19 
and Lassa outbreaks of the current decade where port-
able MinION sequencers generated actionable infor-
mation,41 41–43 and this technology is eminently suitable 
for surveillance of AMR. The diversity of sequencing 
options may well grow but for genomic surveillance, the 
present challenge is increasing their applicability both 
by increasing the number and types of patient specimens 
that reach this type of analysis as well as the scope of 
stakeholder epidemiologists that can access and use the 
information.
Sequencing requires upstream DNA preparation 
and manipulation steps, which currently limit its use 
in some settings, but progress has been made in minia-
turising and automating these using microfluidic 
devices.27 44 While we can expect these to continue to 
improve and converge into combined, portable devices, 
field- ready WGS platforms still have the same challenges 
as culture and NAAT systems; a given patient must have 
an adequate sample taken to confer high sensitivity. 
Furthermore, WGS creates large data files which need 
analysis at source by highly skilled bioinformaticians 
and adequate internet connectivity. Despite these chal-
lenges, WGS combines advantages of culture and NAAT, 
operating in the absence of bacteriology- specific labora-
tory infrastructure while retaining the relative speed of 
NAAT, and the diverse diagnostic capability of culture 
WGS provides finetyping information for any species 
along with identification and susceptibility data at no 
additional cost.45
Current routine application of WGS in AMR surveil-
lance uses sequence derived from isolates. A bigger 
leap can be made by sequencing direct- from- specimen 
(figure 1). This has been accomplished for LMIC speci-
mens, generating in the case of meningitis, valuable infor-
mation that would not otherwise have been obtained.46 
It is, however, costlier because specimens contain a lot 
of reaction inhibitors, including host and commensal 
cells, all of which contain non- target DNA. Therefore, 
direct- from- specimen sequencing requires enriching for 
pathogen DNA in silico after expensively generating total 
metagenomic DNA or enriching for pathogen DNA in 
clinical specimens before sequencing, an approach that 
is still in development.
DATA COLLECTION AND SHARING
Acquiring and managing metadata is often a more diffi-
cult challenge than obtaining rich laboratory data, even in 
resource- rich settings.47 Many LMIC health facilities use 
handwritten patient records in hard copy files, making 
it challenging to retrieve and use meta- data associated 
with laboratory bacterial isolates. A first prerequisite for 
the leap into effective surveillance is electronic record- 
keeping in clinics and labs. Given the range of tests and 
possible results, the technical requirements for micro-
biology laboratory information management systems 
(LIMS) are somewhat broader than those required for 
the blood sciences.48 Purpose- built electronic micro-
biology LIMS systems are uncommon5 12 and there are 
few comprehensive open source or low cost options 
available. Thus, generating pathogen- susceptibility data 
sets or reports for sharing locally, nationally and inter-
nationally remains challenging.49 In the absence of a 
LIMS, WHONET provides a robust solution for stand-
ardised AMR data capture, deduplication, analysis and 
sharing. Where automated analysis tools are in use, some 
instruments can be connected directly to the internet 
or converted using BacLink to WHONET50 and fed into 
surveillance.
When paper records are still used, the supplemen-
tary task of data entry by overstretched health workers 
can be automated by technologies like DataFax (Clinical 
DataFax Systems, Canada). Encryption can be added into 
the communication between mobile phones and a local 
server (which could be just a single computer) in the 
hospital to ensure that personal information of patients 
remain secure. Collection of patient metadata in the 
context of global antimicrobial resistance surveillance 
system- based AMR surveillance was successfully imple-
mented recently at a tertiary centre in Thailand.51 App- 
based collection of clinical data by surveillance staff took 
an average of 10 min per patient and led the authors to 
conclude that such surveillance might be best conducted 
periodically, rather than continuously, to monitor trends. 
Further work is ongoing to define the optimal clinical 
variable data set to efficiently determine key patient- level 
impacts of AMR.52
Data generated from instruments (eg, GeneXpert 
BioFire, Phoenix, Sensititre or VITEK) or from bioinfor-
matic sequence analysis can be connected to surveillance 
systems. This reduces the burden of surveillance on diag-
nostic services, and can also serve as early- warning systems 
for outbreaks by reducing the time lag between data 
collection and reporting.14 53 However, integrating data 
from different platforms can sometimes be challenging 
and is also an area where concerted innovation is neces-
sary. Verification and linkage of clinical and laboratory 
data using open source middleware/ automated scripts, 
coupled with visualisation via user- friendly reports and 
interactive dashboards, permits standardised preparation 
of data for sharing and improved understanding of the 
local AMR situation and its impacts. Several such tools 
are under development, for example the AutoMated 
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tool for Antimicrobial resistance Surveillance System.54 
With the right system, resistance surveillance data can 
be shared with clinicians directly via data visualisations/
reports and indirectly via development of local antimi-
crobial treatment apps, which provide an opportunity for 
further buy- in.49 55
COMMUNITY SURVEILLANCE: LEAPFROGGING PATIENTS
We began this article by outlining pre- laboratory, labora-
tory and dissemination hurdles that need to be overcome 
for AMR surveillance. Surveillance of the environment 
has the advantage of bypassing many hurdles entirely 
but does not take advantage of, or contribute to clin-
ical patient management. An international sewage study 
recently mapped geographical distribution of AMR genes 
garnered from sewage system metagenomes and another 
metagenomic study is surveilling resistance via public 
transportation systems.56 57 Community surveillance 
disconnects surveillance from clinical practice (with the 
possible exception of those that surveil health facilities58) 
and, in low- income countries, privileges better resourced 
communities, which have sewerage, public transport 
networks and concentrate resistance genes at tertiary 
care referral health centres. It also does not deconvolute 
human and animal resistance reservoirs, which may not 
be the same.59 However, community surveillance can use 
specimens other than sewage, and stations and may be an 
inexpensive and non- obtrusive way to measure and map 
resistance, disease or both.58 60–62 Rationale and justifica-
tion needs careful consideration: building community 
surveillance along these lines does not simultaneously 
enhance patient care, which makes it less justifiable in 
parts of the world where patient testing is highly desir-
able but barely available.
ELEPHANTS IN THE ROOM: COST AND LOGISTICAL HURDLES
Traditional culture and susceptibility testing carries many 
indirect and hidden costs; but the cost of sequence- 
based and disposable point- of- care tests are still pres-
ently higher and need to fall before these methods 
can be broadly applied. If the rate of cost decline for 
sequencing continues, it will become cheaper than 
conventional bacteriology within a decade. However, 
culture and susceptibility resources are almost certainly 
likely to be needed to support leapfrog technologies that 
could broaden access to bacteriology diagnostics. For this 
reason, we are not proposing that efforts to develop and 
strengthen laboratories along the traditional paradigm 
should be halted or slowed. Preparing to add on leapfrog 
technologies could lead to overall system strengthening 
that will benefit current and future practices for AMR 
surveillance.
As with financial systems, lab- clinic interfaces and data 
handling in many low- income settings have changed 
marginally, if at all, since colonial times when patient 
and surveillance needs in no way constituted an actual 
health system.63 Health systems and the laboratories 
within them need to move to efficient, patient- centred 
electronic data systems. Cheaper end- user hardware like 
netbooks and tablets makes it possible to do so without 
heavy infrastructure investment. Internet connectivity, an 
overarching hurdle that must be scaled for many other 
purposes, may be the greatest barrier to data access and 
use in some settings.
It can take relatively well- prepared and resourced LMIC 
tertiary care systems years from goal conception to gener-
ating local sequence- based surveillance data. Therefore, 
with the anticipated drop in prices, less endowed systems 
would be wise to begin to make essential but inexpensive 
preparations to shift to or, in the event that they have 
no surveillance, adopt newer technologies. Some of the 
most useful ways to poise to leap include:
1. Update financial practices and supply chains: 
Outdated systems do not serve present- day needs and 
would not be agile enough to procure library prepara-
tion and sequencing reagents in bulk, the best way to 
secure competitive pricing. Financial system develop-
ment that has begun in academia to address these gaps 
for research (https://www. aasciences. africa/ ggc/ stan-
dard) needs to extend to health system procurement, 
human resource and financial management.
2. Applying and exploiting molecular testing requires a 
foundation in molecular sciences that is often absent 
or inadequate in LMIC curricula and continuing ed-
ucation programmes. Developing this expertise now 
would make it easier for LMIC systems to make rapid 
and informed transitions to or adoptions of new tech-
nologies.
3. Health systems need to move to electronic record 
keeping for patient care and in labs, exploiting free ap-
proaches and tools such as WHONET and ACORN.50 52
4. Many of the cost and access issues surrounding ma-
terials required for leapfrog science arise because 
of the present dependence on external resources. 
Development of local systems and implementation sci-
ence to better adapt existing systems is not only possi-
ble, but an urgent health system need. In performing 
clinical diagnostics and surveillance of dolutegravir- 
resistant HIV, Seatla et al developed a ‘home brew’ 
that allowed them to identify mutations with slightly 
elevated sensitivity and only a fraction of the cost of 
commercial kits. In doing so, they turned a technically 
appropriate LMIC technology to one that was econom-
ically feasible, analogous to the development of low 
cost smart phones that are targeted directly at LMIC 
markets and have leapfrogged access to the internet 
in many of these settings. Similar research and innova-
tion may have to precede more widespread adoption 
of leapfrog technologies.
CONCLUSION
Traditional methods for AMR surveillance can be chal-
lenging to establish and truly representative, high quality 
surveillance may be easier to achieve by combining 
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those approaches with new innovations or exploring 
entirely novel paths to usable resistance information. 
Surveillance systems that are starting from scratch have 
the best opportunity to adopt next generation of AMR 
surveillance technologies and should be encouraged and 
supported to embrace newer approaches rather than 
to automatically model surveillance systems on age- old 
frameworks. Where immediate adoption may not yet 
be feasible, active preparation to integrate cost- effective 
technologies should be an immediate priority.
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